Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.

Autor:	Gambaro K; Canadian National Centres of Excellence-Exactis Innovation, Montreal, QC, Canada., Groleau M; Knight Therapeutics Inc., Montreal, QC, Canada., McNamara S; Canadian National Centres of Excellence-Exactis Innovation, Montreal, QC, Canada., Awan A; The Ottawa Hospital, Ottawa, ON, Canada., Salem M; Horizon Health Network-The Moncton Hospital, Moncton, NB, Canada., Abdelsalam M; Horizon Health Network-The Moncton Hospital, Moncton, NB, Canada., St-Hilaire E; Centre Hospitalier Universitaire Dr. Georges-L.-Dumont, Moncton, NB, Canada., Vincent F; Centre Hospitalier Régional de Trois-Riviéres, Trois-Riviéres, QC, Canada., Carrier J; Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada., MacKay H; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Provencher L; Centre Hospitalier Universitaire de Québec, Québec City, QC, Canada., Boudreau D; Centre Hospitalier Universitaire de Québec, Québec City, QC, Canada., Hamilou Z; Centre Hospitalier Universitaire de Montréal, Montreal, QC, Canada., Saad F; Centre Hospitalier Universitaire de Montréal, Montreal, QC, Canada., Ferrario C; Segal Cancer Centre-Jewish General Hospital, Montreal, QC, Canada., Batist G; Segal Cancer Centre-Jewish General Hospital, Montreal, QC, Canada., Marques M; Canadian National Centres of Excellence-Exactis Innovation, Montreal, QC, Canada.
Jazyk:	angličtina
Zdroj:	Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques [J Pharm Pharm Sci] 2023 Dec 13; Vol. 26, pp. 12078. Date of Electronic Publication: 2023 Dec 13 (Print Publication: 2023).
DOI:	10.3389/jpps.2023.12078
Abstrakt:	There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line treatment patterns in HER2-positive metastatic breast cancer (mBC) patients in Canada. The purpose was to assess evolution of clinical practice and identify unmet needs in post-second-line therapy. Retrospective data from medical records of 66 patients who received third-line treatment before 31st October 2018, and data from 56 patients who received third-line treatment after this date, extracted from the Personalize My Treatment (PMT) cancer patient registry, were analyzed. In the first cohort, the study revealed heterogeneity in the third-line setting, with trastuzumab, lapatinib, and T-DM1 being the main treatment options. Even though data were collected before the wide availability of tucatinib, neratinib and trastuzumab deruxtecan in Canada, the PMT cohort revealed the emergence of new therapeutic combinations and a shift from lapatinib usage to T-DM1 choice was observed. These findings underscore the evolving nature of third-line treatment strategies in Canada, a facet that is intrinsically tied to the availability of new drugs. The absence of a consensus on post-second-line treatment highlights the pressing need for more efficient therapeutic alternatives beyond the currently available options. This study not only offers valuable insights into the present landscape of third-line treatment in Canada but validates the significance and effectiveness of the PMT registry as a tool for generating pan-Canadian real-world evidence in oncology and its capacity to provide information on evolution of therapeutic practices. Competing Interests: Author MG was employed by company Knight Therapeutics Inc. This study received funding from Knight Therapeutics Inc. Knight Therapeutics had the following involvement with the study: CR cohort patient selection design and review of the manuscript. (Copyright © 2023 Gambaro, Groleau, McNamara, Awan, Salem, Abdelsalam, St-Hilaire, Vincent, Carrier, MacKay, Provencher, Boudreau, Hamilou, Saad, Ferrario, Batist and Marques.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu